LMR Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$52.7M Buy
57,300
+39,500
+222% +$40M 0.12% 94
2025
Q4
$19.1M Buy
17,800
+14,800
+493% +$14.2M 0.04% 213
2025
Q3
$2.29M Sell
3,000
-142,400
-98% -$106M 0.01% 694
2025
Q2
$113M Buy
145,400
+85,800
+144% +$66.7M 0.81% 17
2025
Q1
$49.2M Buy
59,600
+4,100
+7% +$3.41M 0.46% 38
2024
Q4
$42.8M Buy
55,500
+10,500
+23% +$8.69M 0.36% 46
2024
Q3
$39.9M Buy
+45,000
New +$40.5M 0.32% 56
2024
Q1
Sell
-11,700
Closed -$6.82M 1244
2023
Q4
$6.82M Sell
11,700
-28,200
-71% -$16.5M 0.08% 250
2023
Q3
$21.4M Hold
39,900
0.24% 103
2023
Q2
$18.7M Buy
+39,900
New +$16.7M 0.21% 108

Other funds holding LLY

LMR Partners's LLY Position: Q1 2026 in Review

LMR Partners increased its Eli Lilly (LLY) stake by 748% in Q1 2026, buying an estimated $83.6M and bringing the position to 93,539 shares worth $86M. The position accounts for 0.19% of the portfolio, ranked #53.

LMR Partners first reported a position in LLY in Q2 2015 and has held it in 23 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • LMR Partners held 93,539 shares of Eli Lilly worth $86M as of Q1 2026.
  • LMR Partners bought 82,507 Eli Lilly shares in Q1 2026, an estimated $83.6M.
  • Eli Lilly made up 0.19% of LMR Partners's portfolio in Q1 2026, its #53 holding.
  • LMR Partners first reported a position in Eli Lilly in Q2 2015 and has held it in 23 quarters since.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.